Steris ((STE)) has held its Q3 earnings call. Read on for the main highlights of the call.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
STERIS Earnings Call Reveals Mixed Sentiment Amid Strong Revenue Growth and Challenges
The latest earnings call from STERIS presented a mixed sentiment, balancing strong revenue growth and improved gross margins against challenges such as declining EBIT margins and segment-specific revenue decreases. The company showcased positive trends in free cash flow and growth within the AST segment, yet faced ongoing litigation expenses and adverse currency impacts.
Revenue Growth
The company reported a robust 6% year-over-year increase in total revenue, with constant currency organic revenue also rising by 6%. This growth was primarily driven by volume and price increases, showcasing the company’s ability to capitalize on market demands effectively.
Gross Margin Improvement
STERIS experienced a 90 basis point improvement in gross margin compared to the previous year, reaching 44.6%. This increase was attributed to positive price adjustments and enhanced productivity, reflecting operational efficiencies.
Adjusted Earnings Per Share Increase
There was an 11% increase in adjusted earnings per diluted share from continuing operations, reaching $2.32. This highlights STERIS’s ability to generate profit from its existing operations, despite external pressures.
Healthcare Revenue Growth
The healthcare segment saw a 7% growth in constant currency organic revenue, driven by robust recurring revenue streams. This segment continues to be a strong performer for STERIS, capitalizing on consistent demand in healthcare services.
AST Segment Growth
The AST segment reported a 10% growth in constant currency organic revenue, fueled by a similar increase in services. This underscores the segment’s critical role in the company’s overall revenue expansion.
Strong Free Cash Flow
STERIS generated $588 million in free cash flow over the first nine months of fiscal 2025, aligning well with their full-year guidance of $700 million. This strong cash flow position highlights the company’s financial stability and operational efficiency.
EBIT Margin Decline
Despite other financial successes, the EBIT margin saw a slight decline of 10 basis points to 23.3%, attributed to litigation expenses and increased healthcare benefit costs. This indicates areas where the company needs to manage costs more effectively.
Healthcare Capital Equipment Revenue Decline
Revenue from healthcare capital equipment fell by 5%, primarily due to shipment timing delays. These operational hiccups highlight logistical challenges that STERIS needs to address.
Life Sciences Revenue Decline
The Life Sciences segment experienced a 1% decline in constant currency organic revenue, driven by a decrease in capital equipment revenue. This suggests a need for strategic planning to enhance growth in this segment.
Currency Exchange Impact
Changes in currency exchange rates negatively impacted both revenue and profit expectations, emphasizing the need for STERIS to manage its international financial strategies more effectively.
Litigation and Legal Expenses
Significant legal expenses were incurred due to the ethylene oxide trial, with expectations of continued legal costs in the upcoming quarter. This remains a financial burden that the company must navigate carefully.
Forward-Looking Guidance
In the forward-looking guidance, STERIS reiterated a 6% growth outlook for total revenue and constant currency organic revenue, despite currency exchange challenges. The company maintained its free cash flow forecast at approximately $700 million, showcasing confidence in its financial resilience. STERIS also highlighted a strong backlog in healthcare orders, which bodes well for future revenue, although some shipment delays remain a concern.
In conclusion, the STERIS earnings call painted a complex picture of financial health. While the company demonstrated significant revenue growth and operational improvements, it also faces challenges such as declining EBIT margins and ongoing legal expenses. The forward-looking guidance remains cautiously optimistic, signaling confidence in the company’s ability to navigate current obstacles while leveraging its strengths.
